MedTrace Logo

Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome Signatures

NCT05393102 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-05-26

No results posted yet for this study

Summary

As a prospective, multi-center study, GUIDER will recruit 400 liver nodules participants from different provinces and regions across China. Except for cfDNA signatures, serum biomarkers, histopathological biopsy and enhanced MRI will also be performed. The sensitivity and specificity of the cfDNA signature based-model in liver nodules diagnosing will be evaluated.

Conditions

  • Focal Liver Lesions

Interventions

OTHER

No interventions

No interventions

Sponsors & Collaborators

  • Eastern Hepatobiliary Surgery Hospital

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Chongqing Medical University

    lead OTHER

Principal Investigators

  • Hong Ren, MD · The Second Affiliated Hospital of Chongqing Medical University

  • Hongyang Wang, MD · Eastern Hepatobiliary Surgery Hospita

  • Jinlin Hou, MD · Nanfang Hospital, Southern Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2023-04-30
Completion
2023-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393102 on ClinicalTrials.gov